The strategic partnership with Tri-I TDI, a cooperative endeavor of Memorial Sloan Kettering Cancer Center, The Rockefeller University, and Weill Cornell Medicine, will specifically focus on the early stages of compound and biologic agent development.
“Charles River is opening new pathways to support frontier science and innovation within the drug discovery ecosystem,” Julie Frearson, Executive Director Discovery Global Business Development and Scientific Affairs at Charles River, told Outsourcing-Pharma.com.
“Through this partnership, we bring a robust portfolio of capabilities and decades of experience in drug discovery and safety assessment to the table. Together with TriTDI’s novel drug discovery model, we offer the opportunity to evaluate novel therapeutic concepts in a time and capital efficient manner,” she added.
The company’s next steps will focus on leveraging a combination of project ideas from TRiTDI and execution capabilities and drug discovery experience from Charles River. Frearson explained the companies are currently identifying “high priority areas and projects where this partnership can make a significant impact.”
It is also exploring joint initiatives that will create “synergies” within Tri-I TDI’s Tri institutional community and ecosystem.
“We are very pleased with this opportunity,” added Frearson. “This new partnership model shares goals similar to a biopharma/academic partnership that will populate the R&D pipeline and shorten drug development timelines.”